HC Wainwright Comments on Immix Biopharma, Inc.’s Q2 2024 Earnings (NASDAQ:IMMX)

Immix Biopharma, Inc. (NASDAQ:IMMX) – Stock analysts at HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for Immix Biopharma in a research note issued to investors on Monday, July 1st. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.67) EPS.

Immix Biopharma Stock Down 7.5 %

Shares of IMMX stock opened at $1.96 on Wednesday. The stock’s 50-day moving average is $2.15 and its two-hundred day moving average is $3.36. Immix Biopharma has a 1 year low of $1.55 and a 1 year high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01.

Institutional Investors Weigh In On Immix Biopharma

A number of institutional investors have recently added to or reduced their stakes in IMMX. Private Advisor Group LLC purchased a new stake in Immix Biopharma in the 4th quarter valued at approximately $690,000. Tritonpoint Wealth LLC purchased a new stake in Immix Biopharma in the 1st quarter valued at approximately $75,000. Jump Financial LLC purchased a new stake in Immix Biopharma in the 4th quarter valued at approximately $128,000. Tocqueville Asset Management L.P. boosted its holdings in Immix Biopharma by 89.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock valued at $116,000 after purchasing an additional 17,800 shares in the last quarter. Finally, Imprint Wealth LLC boosted its holdings in Immix Biopharma by 49.4% in the 4th quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock valued at $239,000 after purchasing an additional 11,400 shares in the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.